High-Dose Intravenous Immunoglobulin (IVIG) Adjuvant Therapy for Cell-Mediated Pancreas Transplant Rejection

Untreated pancreas transplant rejection is a barrier to long-term graft survival. Conventionally, cell-mediated rejection in pancreas transplantation can be mitigated by intravenous corticosteroids and rabbit antithymocyte globulin (rATG). In contrast to cellular rejection, antibody-mediated rejection requires anti-CD20 monoclonal antibodies, plasmapheresis, and intravenous immunoglobulin (IVIG). High-dose IVIG possesses broad anti-inflammatory properties, making it suitable for treating rejection. Herein, we report the first documented case of successful adjuvant therapy for pancreas transplant cell-mediated rejection using high-dose IVIG (read more) Print this post